CN103705568A - Compound levofloxacin hydrochloride soluble powder for treating respiratory diseases of poultry - Google Patents
Compound levofloxacin hydrochloride soluble powder for treating respiratory diseases of poultry Download PDFInfo
- Publication number
- CN103705568A CN103705568A CN201310728697.XA CN201310728697A CN103705568A CN 103705568 A CN103705568 A CN 103705568A CN 201310728697 A CN201310728697 A CN 201310728697A CN 103705568 A CN103705568 A CN 103705568A
- Authority
- CN
- China
- Prior art keywords
- soluble powder
- levofloxacin
- poultry
- percent
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses compound levofloxacin hydrochloride soluble powder for treating respiratory diseases of poultry. The soluble powder is prepared by uniformly mixing the following components in percentage by weight: 2-10 percent of levofloxacin hydrochloride, 2-10 percent of azithromycin, 2-6 percent of venenum bufonis, 10-30 percent of liquorice extract, 3-9 percent of Kameiding, 1-5 percent of trimethoprim lactate, and the balance of pharmaceutically applicable auxiliaries. The compound preparation is compounded by latest market medicines, traditional Chinese medicinal extracts, novel antiasthmatic drugs and medicinal synergistic agents, and fatal factors are comprehensively taken, so that the compound levofloxacin hydrochloride soluble powder has the effects of anti-inflammation, sterilization, anti-virus, heart strengthening, cough relieving and allergic reaction resistance, can be used for improving the anti-disease immunity of poultry, repairing injured mucous membrane and effectively controlling secondary infection, and has an effective treatment effect to respiratory diseases of poultry.
Description
Technical field
The present invention relates to a kind of fowl medicine, particularly relate to a kind of compound hydrochloric acid levofloxacin soluble powder that is used for the treatment of poultry respiratory system disease.
Background technology
Poultry diseases of respiratory system refers to performance obvious respiratory symptom (as sneeze, snore, asthma, ataxia) or take respiratory symptom as main disease (propping up, pass larynx, chronic respiratory diseases etc. as newcastle, influenza, biography).Therefore can say that respiratory tract disease is the general name of a class disease, although this class disease all shows respiratory symptom, their cause of disease is different, and quite complicated.Broiler industry especially in aviculture, respiratory tract disease is unreasonable, the most thorny disease, also numerous raisers are concerned about most, because not only difficult diagnosis and treatment of this class disease, and be easy to get very much, almost criticize the generation that chicken all can be in various degree, and cause certain economic loss.Therefore, respiratory tract disease has become the primary disease that endangers aviculture at present.
Because respiratory system disease can be passed through air borne, its spread speed is very fast, and the treatment of respiratory system disease is very thorny clinically, so we must find the reason of morbidity, in medication, improve the condition of feeding and management, thereby reach the effect for the treatment of both the principal and secondary aspects of a disease.Be below the reason that several frequently seen respiratory system disease is fallen ill:
(1) environmental factors: the respiratory tract disease that feeding and management is not good at or stressors causes, the height of feeding and management level has great relation with Abwehrkraft des Koepers power.As the saying goes: " stress be the source of ten thousand diseases ".What is called stress, be exactly bad feeding and management factor.Cause that stress mainly containing of respiratory tract disease is following several:
Cold stress: as weather cooling, thermal source breaks down, the factor such as ventilate excessive and indoorly have harmful wind or draught to cause the warm fusion of house to cause the respiratory symptoms such as sneeze, cough.
Improper ventilation: dust and harmful gas (ammonia, hydrogen sulfide, carbon dioxide etc.) too high levels in house, especially at feeding of broiler later stage chicken group outeat, row's feces is also many, if bedding and padding, feces are removed not in time, adds the individuality increase of chicken, relative density also increases, make like this source of giving up interior generation harmful gas increase, if improper ventilation now, harmful gas concentration is too high, stimulate respiratory mucosa, cause respiratory symptom.
In pouity dwelling place, density is too high: mention above, density height not only affects growth, also can cause the cause of disease that causes respiratory tract disease more easily to be propagated, chicken group susceptible disease, and it is too dry easily to peck the interior air of house, this kind of situation house of brooding is more common, and because brooding, house temperature is higher, and chickling excretion is lacked, if manually do not improve humidity, make to give up inner drying, easily cause chickling mucosa xerosis, occur the symptoms such as asthma, dry cough.When band chicken spraying disinfection, use the large disinfectant of zest: as chloride class, lysol etc., can stimulate respiratory mucosa, cause respiratory symptom.
The respiratory tract disease that vaccine improper use causes: strong malicious Seedling repeatedly, during Use out of range, may cause pathogen in body to be accumulated, causes vaccine virus to infect.
To sum up, above stressors, all can stimulate respiratory mucosa, not only caused corresponding respiratory symptom, also made the resistance of respiratory mucosa reduce simultaneously, now some pathogenic microorganisms (as antibacterial, mycoplasma) all can be availed oneself of the opportunity to get in, cause more serious infectious respiratory disease, now, it is invalid in the treatment time, throwing the medicines such as antibiotic, must coordinate the improvement of environment just can obtain good effect.
(2) respiratory tract disease being caused by pathogenic microorganism (virus, antibacterial and mycoplasma etc.): newcastle, bird flu, infectious bronchitis, infectious laryngotracheitis, chronic respiratory tract disease, infective rhinitis, colibacillosis etc. have respiratory symptom performance, but their cause of disease is different.And more complicated be two or more respiratory pathogen simultaneously or successively act on chicken respiratory, between them, can produce pathogenic synergism, much more serious than single pathogen associated diseases.Especially some immunosuppressive disease are as Marek, infectious bursal disease, infectious anemia, leukemia, newcastle, bird flu etc., while there is again immunosuppressant pathogen in the chicken group of generation respiratory tract disease, respiratory tract disease can be very serious, and uncontrollable.
At present, along with the high density of aquaculture is intensive and cultivating condition relatively backward, the difficulty of livestock and poultry cultivation is increasing, and respiratory system disease is due to can air-borne transmission, and feature multiple, occurred frequently becomes one of problem demanding prompt solution in current aquaculture.At present, the epidemic disease that plant occurs is no longer a certain typical infectious disease, but the mixed infection that multiple pathogens combined effect causes, and raise the secondary infection that the later stage brings, this has just brought great difficulty to clinical diagnosis, also makes the effect of single medicine can not meet clinical needs at present.Meanwhile, because antibiotic for a long time, at the abuse aspect livestock and poultry cultivation, makes the problem of Resistant strain more and more serious.
Summary of the invention
The object of the invention is to overcome above-mentioned weak point, provide a kind of efficient, quick-acting, without drug resistance, treating both the principal and secondary aspects of a disease for preventing and treating the Compound Levofloxacin soluble powder of poultry respiratory system disease.
The technical scheme that the present invention solves its technical problem is: a kind of Compound Levofloxacin soluble powder for the treatment of poultry respiratory system disease, this soluble powder is made by following component mix homogeneously by weight percentage: levofloxacin hydrochloride 2～10%, azithromycin 2～10%, Venenum Bufonis 2～6%, Radix Glycyrrhizae extract 10～30%, block U.S. fourth 3～9%, Trimethoprim lactate 1～5%, surplus is pharmaceutically applicable adjuvant.
Preferably, described soluble powder is made by following component mix homogeneously by weight percentage: levofloxacin hydrochloride 3～9%, Azithromycin 4～8%, Venenum Bufonis 3～5.5%, Radix Glycyrrhizae extract 11～25%, block U.S. fourth 4～8%, Trimethoprim lactate 2～4%, surplus is pharmaceutically applicable adjuvant.
Preferably, described soluble powder is made by following component mix homogeneously by weight percentage: levofloxacin hydrochloride 4～7%, azithromycin 3～9%, Venenum Bufonis 4～5%, Radix Glycyrrhizae extract 15～20%, block U.S. fourth 5～7%, Trimethoprim lactate 1.5～3.5%, surplus is pharmaceutically applicable adjuvant.
Preferably, described soluble powder is made by following component mix homogeneously by weight percentage: levofloxacin hydrochloride 8%, azithromycin 6%, Venenum Bufonis 4.5%, Radix Glycyrrhizae extract 18%, block U.S. fourth 6%, Trimethoprim lactate 3%, surplus is pharmaceutically applicable adjuvant.
Preferably, described soluble powder is made by following component mix homogeneously by weight percentage: levofloxacin hydrochloride 2%, azithromycin 7%, Venenum Bufonis 4%, Radix Glycyrrhizae extract 20%, block U.S. fourth 5%, Trimethoprim lactate 2%, surplus is pharmaceutically applicable adjuvant.
Preferably, described pharmaceutically applicable adjuvant is at least a kind of in sucrose, anhydrous glucose, oral glucose, starch.
Preferably, described pharmaceutically applicable adjuvant is anhydrous glucose.
Preferably, described pharmaceutically applicable adjuvant is anhydrous grape sugar and starch, and the weight ratio of described anhydrous grape sugar and starch is 1:1.
The pharmacological property that the present invention respectively forms medicine is analyzed as follows:
Levofloxacin hydrochloride: the levo form of levofloxacin hydrochloride, its antibacterial activity is about the twice of ofloxacin, and its main mechanism is the activity of anti-bacteria DNA gyrase (antibacterial typeⅡtopoisomerase), hinders bacterium DNA replication.This product has broad-spectrum antibacterial action, antibacterial action is strong, to most enterobacteriaceae lactobacteriaceaes, as the gram-negative bacterias such as escherichia coli, Klebsiella, Proteus, Salmonella, Shigella and hemophilus influenza, Diplococcus gonorrhoeae have stronger antibacterial activity.The gram positive bacterias such as staphylococcus aureus, streptococcus pneumoniae, micrococcus scarlatinae and mycoplasma pneumoniae, Chlamydia pneumoniae are also had to antibacterial action.
Azithromycin: azithromycin is macrolide antibiotics, its mechanism of action is to be combined by the ribosomal subunit of the 50s with sensitive microbial, thereby disturbs the synthetic of its protein.Be applicable to sinusitis, acute bronchitis, acute episode of chronic bronchitis that sensitive bacterial causes; Pneumonia due to streptococcus pneumoniae, hemophilus influenza and mycoplasma pneumoniae; The acute pharyngitis that micrococcus scarlatinae causes, acute tonsillitis etc.
Venenum Bufonis
:venenum Bufonis is to be processed from strand by the ear rear gland of the amphibious reptile of Bufonidae and skin gland secretion thing, is Chinese medicine material.Several functions such as the bioactive substances such as the contained steroidal thing of Venenum Bufonis, alkaloid have removing toxic substances, ease pain, have one's ideas straightened out, antitumor and being widely used.Venenum Bufonis mainly contains following effect:
(1) respiratory stimulant and boosting: bufogenin, Toadpoison Medicine and cinobufacin etc. all have significant respiratory stimulant and the central excitation effect such as boost, the bufogenin of wherein especially usining is used as respiratory stimulant clinically, bufogenin has direct excitation to stingy in patient's breathing and vasomotor center, also have heart tonifying, rising blood pressure, and effect is lasting rapidly, clinically for respiratory failure, shock, dyspnea and QI rising in reverse order etc. poisoning, drowned, that stupor causes.
(2) antiinflammatory action: Venenum Bufonis sterols substance suppresses vascular permeability, and redness is around disappeared, obviously, rapidly, insensitive or antibiotic has been produced to the suppurative illness of drug resistance to some antibiotic, these product also have inhibition to fungistatic effect.Venenum Bufonis suppresses the effect that granulation forms in addition, to burn and other wound, share with anti-infective, can receive good antiphlogistic effects.And can suppress capillary permeability and increase, reduce inflammatory exudation, be of value to elimination swelling.It was also reported, Toadvenom can activate mouse peritoneal wandering macrophage, improves its phagocytic activity, and the known macrophage being activated and processing antigen, can directly kill antibacterial and bacteria growing inhibiting again.
(3) resisting pathogenic microbes: laboratory report sterols substance suppresses vascular permeability, rabbit to staphylococcus aureus and α-hemolytic streptococcus infection, subcutaneous injection Venenum Bufonis Injection can stop focus diffusion, to the tissue blood vessel permeability that stimulated by acetic acid is hyperfunction, has an inhibitory action.
(4) impact on immunologic function: the monomer separation of the total composition of Venenum Bufonis water solublity and immunopharmacology thereof and molecular biological research, have the reticuloendothelial system phagocytic of enhancing function, the effect that improves the nonspecific immunity of body.
(5) antitussive effect: bufotenine has anti-allergic effects, Venenum Bufonis decoct has antitussive effect.
Radix Glycyrrhizae extract: Radix Glycyrrhizae is the plant that a kind of medical value is larger, and Chinese and western medicine is all used it.Doctor trained in Western medicine is just used Radix Glycyrrhizae as expectorant, anti-tussive agents and sweetening agent from Gu Xila.Research shows, Radix Glycyrrhizae has the aldose reductase that suppresses monoamine oxidase, MAO, suppresses to cause diabetes, spasmolysis and analgesia, prevents and treats the effects such as viral hepatitis, treatment senile osteoporosis, anti-leishmania, anticancer, anti-AIDS (AIDS) virus.Radix Glycyrrhizae extract is the composition that has medical value extracting from Radix Glycyrrhizae.Radix Glycyrrhizae extract generally comprises: glycyrrhizin, glycyrrhizic acid, liquiritin, flavonoids of Glycyrrhiza, rear curtain are than wingceltis element, formoononetin, Quercetin etc., for yellow is to brown color powder.There is invigorating the spleen and replenishing QI, heat-clearing and toxic substances removing, expelling phlegm for arresting cough, relieving spasm to stop pain, the effect of coordinating the actions of various ingredients in a prescription.Be used for the treatment of weakness of the spleen and stomach, fatigue and weakness, shortness of breath and palpitation, cough with copious phlegm, the diseases such as gastral cavity abdomen, the anxious pain of extremity contraction.
Ka Meiding: Ka Meiding is a kind of novel compound of relievining asthma, the feature that have instant effect (poultry took effect with latter approximately 5 minutes), long half time, noresidue, has no side effect.Its pharmacological action has: (1) removes bronchospasm; (2) it is main multiple inflammatory cell infiltration that antiinflammatory action: Ka Meiding can reduce peripheral blood oxyphil cell (EOS), can obviously resist the synthetic of pro-inflammatory cytokine, reduces the IgE level in asthma animal body, alleviates the reactivity of trachea to anaphylactogen; (3) antiallergic action: asthma is a kind of allergic disease.As initiating effector lymphocyte, there is de-particle reaction in mastocyte, discharge inflammatory mediator (histamine, leukotriene, peroxidase etc.) under antigenic stimulus, cause smooth muscle contraction, mucus hypersecretion, vascular permeability increases, and forms chronic inflammatory reaction and airway hyperreactivity.Ka Meiding can significantly suppress the airway hyperreactivity of sensitized rats Carbamoylcholine induction, suppresses mast cell degranulation reaction, reduces lung tissue and discharges slow reaction substance of anaphylaxis (SRS-A), improves IgG content in serum.This product is applicable to bronchial asthma, asthmatic bronchitis, the acute bronchitis increasing with bronchial reactivity, chronic obstructive disease of lung.
Trimethoprim lactate: the lactate that this product is TMP, its mechanism of action is anti-bacteria dihydrofolate reductase, makes dihydrofoilic acid can not be reduced into tetrahydrofolic acid, stops the synthetic of bacterial nucleic acid.Trimethoprim lactate is combined use with sulphonamides, Tetracyclines, penicillins, erythromycin, gentamycin, fluoroquinolones, can strengthen the antibacterial activity of original medicine, and can also reduce the generation of Resistant strain.
Beneficial effect: the present invention carries out on the basis of large quantity research in the respiratory system disease to multiple clinically, in conjunction with the compatibility activity of antibacterials, put forward, adopt up-to-date marketed drug, Chinese medicine extract, novel suppressing panting calming medicine and medicament synergistic agent to be re-dubbed compound preparation, and carried out abundant checking by a series of clinical trial.By three-dimensional prescription, many infection reasons are considered careful, do not allow a kind of pathogenic microorganism slip through the net, effect by antitussive, raising immunity of organisms reaches the object for the treatment of both the principal and secondary aspects of a disease simultaneously, fatal factor is considered comprehensively, antiinflammatory, sterilization, antiviral, heart tonifying, antitussive, antiallergic action, promote poultry anti pathologic immunity power, repair impaired mucosa, effectively control secondary infection, and poultry respiratory system disease is had to efficient therapeutical effect.The present invention fills a prescription rationally, science, preparation is simple, effect is remarkable, be widely used, and can be used as the choice drug of prevention and treatment poultry respiratory system disease.
The specific embodiment
Below in conjunction with preferred embodiment, the present invention will be further described.
Embodiment 1: according to following proportioning, take respectively raw material: levofloxacin hydrochloride 5g, Azithromycin 4 g, Venenum Bufonis 4g, Radix Glycyrrhizae extract 25g, block U.S. fourth 5g, Trimethoprim lactate 4g; Add anhydrous glucose to 100g, mix homogeneously, makes the specific Compound Levofloxacin soluble powder that is used for the treatment of poultry respiratory system disease of a kind of tool.The weight ratio of described anhydrous glucose and oral glucose is 1:1, and described raw material is commercially available prod.
Embodiment 2: according to following proportioning, take respectively raw material: levofloxacin hydrochloride 2.5g, azithromycin 2.5g, Venenum Bufonis 3g, Radix Glycyrrhizae extract 29g, block U.S. fourth 8g, Trimethoprim lactate 1g; Add anhydrous glucose and oral glucose to 100g, mix homogeneously, makes the specific Compound Levofloxacin soluble powder that is used for the treatment of poultry respiratory system disease of a kind of tool.The weight ratio of described anhydrous glucose and oral glucose is 1:1, and described raw material is commercially available prod.
Embodiment 3: according to following proportioning, take respectively raw material: levofloxacin hydrochloride 9g, azithromycin 8g, Venenum Bufonis 5.5g, Radix Glycyrrhizae extract 11g, block U.S. fourth 3g, Trimethoprim lactate 4.8g; Add anhydrous glucose and oral glucose to 100g, mix homogeneously, makes the specific Compound Levofloxacin soluble powder that is used for the treatment of poultry respiratory system disease of a kind of tool.The weight ratio of described anhydrous glucose and oral glucose is 1:1.Described raw material is commercially available prod.
Embodiment 4: according to following proportioning, take respectively raw material: levofloxacin hydrochloride 4g, azithromycin 7g, Venenum Bufonis 4g, Radix Glycyrrhizae extract 20g, block U.S. fourth 5g, Trimethoprim lactate 2g, add anhydrous glucose, sucrose and starch to 100g, mix homogeneously, makes the specific Compound Levofloxacin soluble powder that is used for the treatment of poultry respiratory system disease of a kind of tool.The weight ratio of described anhydrous glucose, sucrose and starch is 1:1:1.Described raw material is commercially available prod.
Embodiment 5: according to following proportioning, take respectively raw material: levofloxacin hydrochloride 6g, azithromycin 6g, Venenum Bufonis 5g, Radix Glycyrrhizae extract 15g, block U.S. fourth 6g, Trimethoprim lactate 3g; Add anhydrous glucose, sucrose, oral glucose and starch to 100g, mix homogeneously, makes the specific Compound Levofloxacin soluble powder that is used for the treatment of poultry respiratory system disease of a kind of tool.The weight ratio of described anhydrous glucose, sucrose, oral glucose and starch is 1:1:1:1.Described raw material is commercially available prod.
Embodiment 6: according to following proportioning, take respectively raw material: levofloxacin hydrochloride 4.5g, azithromycin 3g, Venenum Bufonis 4.2g, Radix Glycyrrhizae extract 19g, block U.S. fourth 5.1g, Trimethoprim lactate 1.7g; Add anhydrous glucose to 100g, mix homogeneously, makes the specific Compound Levofloxacin soluble powder that is used for the treatment of poultry respiratory system disease of a kind of tool.Described raw material is commercially available prod.
Embodiment 7: according to following proportioning, take respectively raw material: levofloxacin hydrochloride 7g, azithromycin 8.5g, Venenum Bufonis 4.5g, Radix Glycyrrhizae extract 15.5g, block U.S. fourth 5.2g, Trimethoprim lactate 3.5g; Add anhydrous glucose to 100g, mix homogeneously, makes the specific Compound Levofloxacin soluble powder that is used for the treatment of poultry respiratory system disease of a kind of tool.Described raw material is commercially available prod.
Embodiment 8: according to following proportioning, take respectively raw material: levofloxacin hydrochloride 8g, azithromycin 6g, Venenum Bufonis 4.5g, Radix Glycyrrhizae extract 18g, block U.S. fourth 6g, Trimethoprim lactate 3g; Add anhydrous glucose and starch to 100g, mix homogeneously, makes the specific Compound Levofloxacin soluble powder that is used for the treatment of poultry respiratory system disease of a kind of tool.The weight ratio of described anhydrous grape sugar and starch is 1:1.Described raw material is commercially available prod.
Embodiment 9: according to following proportioning, take respectively raw material: levofloxacin hydrochloride 2g, azithromycin 7g, Venenum Bufonis 4g, Radix Glycyrrhizae extract 20g, block U.S. fourth 5g, Trimethoprim lactate 2g; Add anhydrous glucose and starch to 100g, mix homogeneously, makes the specific Compound Levofloxacin soluble powder that is used for the treatment of poultry respiratory system disease of a kind of tool.The weight ratio of described anhydrous grape sugar and starch is 1:1.Described raw material is commercially available prod.
Using method of the present invention is: with this product medicine 100g, is watered 500 jin of drinking-water, is used in conjunction 3～5 days, and multiplicable during spice, or spraying treatment.Spray delivery is specially adapted to serious mixed infection, is at death's door, does not eat or drink, the chicken group of serious airsacculitis, evenings 18 spray delivery during ︰ 00 to 20 ︰ 00, to infecting the pathogenic microorganism of respiratory system disease, there is killing action thoroughly, can control at short notice respiratory symptom, reduce chicken group stress, be conducive to chicken group disease recovery.
Claims (8)
1. a Compound Levofloxacin soluble powder for the treatment of poultry respiratory system disease, it is characterized in that: this soluble powder is made by following component mix homogeneously by weight percentage: levofloxacin hydrochloride 2～10%, azithromycin 2～10%, Venenum Bufonis 2～6%, Radix Glycyrrhizae extract 10～30%, block U.S. fourth 3～9%, Trimethoprim lactate 1～5%, surplus is pharmaceutically applicable adjuvant.
2. Compound Levofloxacin soluble powder according to claim 1, it is characterized in that: described soluble powder is made by following component mix homogeneously by weight percentage: levofloxacin hydrochloride 3～9%, Azithromycin 4～8%, Venenum Bufonis 3～5.5%, Radix Glycyrrhizae extract 11～25%, block U.S. fourth 4～8%, Trimethoprim lactate 2～4%, surplus is pharmaceutically applicable adjuvant.
3. Compound Levofloxacin soluble powder according to claim 1, it is characterized in that: described soluble powder is made by following component mix homogeneously by weight percentage: levofloxacin hydrochloride 4～7%, azithromycin 3～9%, Venenum Bufonis 4～5%, Radix Glycyrrhizae extract 15～20%, block U.S. fourth 5～7%, Trimethoprim lactate 1.5～3.5%, surplus is pharmaceutically applicable adjuvant.
4. Compound Levofloxacin soluble powder according to claim 1, it is characterized in that: described soluble powder is made by following component mix homogeneously by weight percentage: levofloxacin hydrochloride 8%, azithromycin 6%, Venenum Bufonis 4.5%, Radix Glycyrrhizae extract 18%, block U.S. fourth 6%, Trimethoprim lactate 3%, surplus is pharmaceutically applicable adjuvant.
5. Compound Levofloxacin soluble powder according to claim 1, it is characterized in that: described soluble powder is made by following component mix homogeneously by weight percentage: levofloxacin hydrochloride 2%, azithromycin 7%, Venenum Bufonis 4%, Radix Glycyrrhizae extract 20%, block U.S. fourth 5%, Trimethoprim lactate 2%, surplus is pharmaceutically applicable adjuvant.
6. according to the Compound Levofloxacin soluble powder described in claim 1-5 any one, it is characterized in that: described pharmaceutically applicable adjuvant is at least a kind of in sucrose, anhydrous glucose, oral glucose and starch.
7. Compound Levofloxacin soluble powder according to claim 6, is characterized in that: described pharmaceutically applicable adjuvant is anhydrous glucose.
8. Compound Levofloxacin soluble powder according to claim 6, is characterized in that: described pharmaceutically applicable adjuvant is anhydrous grape sugar and starch, and the weight ratio of described anhydrous grape sugar and starch is 1:1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310728697.XA CN103705568A (en) | 2013-12-26 | 2013-12-26 | Compound levofloxacin hydrochloride soluble powder for treating respiratory diseases of poultry |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310728697.XA CN103705568A (en) | 2013-12-26 | 2013-12-26 | Compound levofloxacin hydrochloride soluble powder for treating respiratory diseases of poultry |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103705568A true CN103705568A (en) | 2014-04-09 |
Family
ID=50399155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310728697.XA Pending CN103705568A (en) | 2013-12-26 | 2013-12-26 | Compound levofloxacin hydrochloride soluble powder for treating respiratory diseases of poultry |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103705568A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105030882A (en) * | 2015-07-06 | 2015-11-11 | 四川省畜牧科学研究院 | Medicine compound preparation for preventing and treating respiratory diseases of livestock and poultry, and preparation method thereof |
| CN107397748A (en) * | 2017-08-09 | 2017-11-28 | 黄娇英 | A kind of toad cake extract with anti-infectious function and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101450069A (en) * | 2007-11-29 | 2009-06-10 | 天津瑞普生物技术集团有限公司 | Soluble powder for treating poultry respiratory infection |
-
2013
- 2013-12-26 CN CN201310728697.XA patent/CN103705568A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101450069A (en) * | 2007-11-29 | 2009-06-10 | 天津瑞普生物技术集团有限公司 | Soluble powder for treating poultry respiratory infection |
Non-Patent Citations (2)
| Title |
|---|
| 董春花，董俊雄: "鸡呼吸道疾病的防治措施", 《今日畜牧兽医》 * |
| 陈峰: "关于家禽喷雾给药的体会", 《家禽科学》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105030882A (en) * | 2015-07-06 | 2015-11-11 | 四川省畜牧科学研究院 | Medicine compound preparation for preventing and treating respiratory diseases of livestock and poultry, and preparation method thereof |
| CN107397748A (en) * | 2017-08-09 | 2017-11-28 | 黄娇英 | A kind of toad cake extract with anti-infectious function and preparation method thereof |
| CN107397748B (en) * | 2017-08-09 | 2018-10-02 | 黄娇英 | A kind of toad cake extract and preparation method thereof with anti-infectious function |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101698024B (en) | Traditional Chinese medicine for treating respiratory diseases and promoting growth for swine and preparation method thereof | |
| CN105287790A (en) | Paederia scandens extract and applications thereof | |
| CN102920957B (en) | Chinese herbal medicine additive for preventing pig salmonellosis and pig feed using additive | |
| CN102091178B (en) | Traditional Chinese medicine composite for treating respiratory disease and preparation method thereof | |
| CN100546606C (en) | A kind of medicine of preventing and treating fowl's respiratory tract diseases and preparation method thereof that is used to | |
| CN104739963A (en) | Preparation method of Chinese medicinal micro-ecological oral preparation for preventing chicken colibaciuosis | |
| CN105688157A (en) | Traditional Chinese medicine compound preparation for resisting swine influenza virus and preparing method thereof | |
| CN103705568A (en) | Compound levofloxacin hydrochloride soluble powder for treating respiratory diseases of poultry | |
| CN107823326A (en) | A kind of fish pathogens bacteria inhibitor | |
| CN105535406A (en) | Traditional Chinese medicine composition for preventing and treating livestock respiratory disease | |
| CN107970272A (en) | The purposes of pithecellobium clypearia or extract in treatment and/or the bronchopneumonic medicine of auxiliary treatment livestock and poultry is prepared | |
| CN111084862B (en) | Traditional Chinese medicine oral liquid for preventing and treating lung heat cough and asthma of poultry and preparation method thereof | |
| CN107823325A (en) | Fish germ inhibitor | |
| CN109432287B (en) | Traditional Chinese medicine oral liquid for preventing and treating excessive heat syndrome of poultry qi system and preparation method thereof | |
| CN111603514A (en) | Veterinary anti-mycoplasma infection traditional Chinese medicine compound preparation and preparation method and application thereof | |
| CN104352582A (en) | Medicine for preventing and treating colibacillosis of chickens and preparation method thereof | |
| CN105106935A (en) | Compound Flunixin meglumine injection and preparation method thereof | |
| CN1927272A (en) | Medicament for animals with heat clearing and detoxicating, detumescence and obstruction removing functions and preparing method thereof | |
| CN105748873A (en) | Veterinary traditional Chinese medicine particle for treating livestock and poultry respiratory tract infection | |
| CN113491670B (en) | Detoxifying oral liquid for livestock and preparation method thereof | |
| CN103263483B (en) | Medicament used for treating livestock virus and bacteria infections and prepared from traditional Chinese medicines and preparation method of medicament | |
| CN108969648A (en) | A kind of pharmaceutical composition and application method | |
| CN110974878B (en) | Traditional Chinese medicine spray for treating avian infectious rhinotracheitis of green-shell laying hens and preparation method thereof | |
| CN101879179A (en) | Compound Ofloxacin solution and preparation method thereof | |
| CN102327365A (en) | Oral liquid for treating air sacculitis caused by colibacillosis of chicken and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Liu Changdou Inventor after: Cao Sufang Inventor before: Liu Changdou |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: LIU CHANGDOU TO: LIU CHANGDOU CAO SUFANG |
|
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140409 |
|
| RJ01 | Rejection of invention patent application after publication |